Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Immunopathogenesis of lymphoma: focus on CCR4.

Ishida T, Ueda R.

Cancer Sci. 2011 Jan;102(1):44-50. doi: 10.1111/j.1349-7006.2010.01767.x. Epub 2010 Nov 2. Review.

2.

Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.

Ito A, Ishida T, Yano H, Inagaki A, Suzuki S, Sato F, Takino H, Mori F, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R.

Cancer Immunol Immunother. 2009 Aug;58(8):1195-206. doi: 10.1007/s00262-008-0632-0. Epub 2008 Dec 2.

PMID:
19048251
3.

CCR4 as a novel molecular target for immunotherapy of cancer.

Ishida T, Ueda R.

Cancer Sci. 2006 Nov;97(11):1139-46. Epub 2006 Sep 5. Review. Erratum in: Cancer Sci. 2007 Jul;98(7):1137.

4.

Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege.

Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, Inagaki H, Ueda R.

Cancer Res. 2006 Jun 1;66(11):5716-22.

5.

Clinical Application of Anti-CCR4 Monoclonal Antibody.

Ueda R.

Oncology. 2015;89 Suppl 1:16-21. doi: 10.1159/000431059. Epub 2015 Nov 10. Review.

PMID:
26550987
6.

The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma.

Ishida T, Iida S, Akatsuka Y, Ishii T, Miyazaki M, Komatsu H, Inagaki H, Okada N, Fujita T, Shitara K, Akinaga S, Takahashi T, Utsunomiya A, Ueda R.

Clin Cancer Res. 2004 Nov 15;10(22):7529-39.

7.

Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.

Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H, Inagaki A, Suzuki S, Takino H, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R.

J Immunol. 2009 Oct 1;183(7):4782-91. doi: 10.4049/jimmunol.0900699. Epub 2009 Sep 11.

8.

Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.

Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, Biota C, Doffin AC, Durand I, Olive D, Perez S, Pasqual N, Faure C, Ray-Coquard I, Puisieux A, Caux C, Blay JY, Ménétrier-Caux C.

Cancer Res. 2009 Mar 1;69(5):2000-9. doi: 10.1158/0008-5472.CAN-08-2360. Epub 2009 Feb 24.

9.

[Anti-CCR4 mAb and regulatory T cells].

Kurose K, Ohue Y, Oka M.

Gan To Kagaku Ryoho. 2013 Sep;40(9):1150-5. Japanese.

PMID:
24047773
10.

Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma.

Ishii T, Ishida T, Utsunomiya A, Inagaki A, Yano H, Komatsu H, Iida S, Imada K, Uchiyama T, Akinaga S, Shitara K, Ueda R.

Clin Cancer Res. 2010 Mar 1;16(5):1520-31. doi: 10.1158/1078-0432.CCR-09-2697. Epub 2010 Feb 16.

11.
12.

CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified.

Ishida T, Inagaki H, Utsunomiya A, Takatsuka Y, Komatsu H, Iida S, Takeuchi G, Eimoto T, Nakamura S, Ueda R.

Clin Cancer Res. 2004 Aug 15;10(16):5494-500.

13.

Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.

Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, Yamaguchi K, Yamada Y, Hanada S, Tamura K, Nakamura S, Inagaki H, Ohshima K, Kiyoi H, Ishida T, Matsushima K, Akinaga S, Ogura M, Tomonaga M, Ueda R.

J Clin Oncol. 2010 Mar 20;28(9):1591-8. doi: 10.1200/JCO.2009.25.3575. Epub 2010 Feb 22.

14.

Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma.

Jones D, O'Hara C, Kraus MD, Perez-Atayde AR, Shahsafaei A, Wu L, Dorfman DM.

Blood. 2000 Jul 15;96(2):685-90.

15.

Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome.

Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, Takeuchi G, Shimizu S, Ito M, Komatsu H, Wakita A, Eimoto T, Matsushima K, Ueda R.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3625-34.

16.

[CCR4, HTLV-1 infection, and ATL oncogenesis].

Yoshie O.

Uirusu. 2008 Dec;58(2):125-40. Review. Japanese.

17.
18.

Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas.

Tobinai K, Takahashi T, Akinaga S.

Curr Hematol Malig Rep. 2012 Sep;7(3):235-40. doi: 10.1007/s11899-012-0124-3. Review.

19.

CCR4 and its ligands: from bench to bedside.

Yoshie O, Matsushima K.

Int Immunol. 2015 Jan;27(1):11-20. doi: 10.1093/intimm/dxu079. Epub 2014 Aug 2. Review.

PMID:
25087232
20.

Chemokine receptor expression in cutaneous T cell and NK/T-cell lymphomas: immunohistochemical staining and in vitro chemotactic assay.

Yagi H, Seo N, Ohshima A, Itoh T, Itoh N, Horibe T, Yoshinari Y, Takigawa M, Hashizume H.

Am J Surg Pathol. 2006 Sep;30(9):1111-9.

PMID:
16931956
Items per page

Supplemental Content

Write to the Help Desk